GRAIL, Inc.
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by developing pioneering technology to detect and identify multiple deadly cancer types early. The company is using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to enhance the scientific understanding of cancer biology, and to develop its multi-cancer early detection blood test. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom. It is supported by leading global investors and pharmaceutical, technology, and healthcare companies. For more information, please visit www.grail.com.
Menlo Park, CA 94025
Stock Symbol: GRAL
CEO: Bob Ragusa
To pursue a mission like GRAIL’s, it takes a unified collective of courageous, adaptable, and open-minded big thinkers dedicated to creating a better world.
Because we’ve set our sights high, the work we’re doing asks a lot of us. Pursuing scientific breakthroughs, scaling for growth, and driving change across a dynamic operating environment requires next-level creativity and collaboration. It takes agility, courage, curiosity, and humility. It takes tapping into our passion on a daily basis.
We’re looking for smart, passionate people who embrace solving hard problems with urgency to help us achieve our mission.
Are you ready to join us?
On this monthly podcast, we explore topics relating to early cancer detection, including multi-cancer early detection testing, cancer genomics and risk, barriers to cancer screening, and much more.